Financial and other terms of the proposed acquisition were not disclosed.
Proligo, headquartered in
Last year, Proligo had approximately $40 million in sales. The company has manufacturing sites in
"We expect this investment to permit us to participate as a global leader in the genomics and gene-silencing research tools markets for years to come," said David Harvey, Sigma's CEO, in a statement.
The acquisition, which Sigma plans to fund with short-term debt, has already been cleared with both companies' boards of directors. Subject to regulatory approval in